Troriluzole Study


Biohaven will apply for FDA approval for slowing down the progression of SCA using Troriluzole (BHV-4157) previously known as Trigriluzole. I expect this to happen in 2 years or so.

:thinking: Maybe this is linked to their comment ‘patients committing to the study now (Troriluzole or placebo), will be given Troriluzole when the study ends.